Board of directors

Scientific advisory board

  • CEO
    Simon Grant

    Extensive experience within the medical device industry, especially with diagnostic devices where he has focused on commercialization of new clinical technologies. Simon has held senior positions within management and sales and marketing in medtech startups such as Synectics Medical and Neoventa, and in established multinationals such as Medtronic. He has always worked with an international focus, and has been based in Scandinavia, the US and Asia.

  • CFO
    Michael Colérus

    CFO since 2014. Born: 1962. Education: B.Sc. (Econ), Uppsala University. Experience: Michael Colérus was previously CFO for Aerocrine AB and in that capacity took Aerocrine public in 2007 on Nasdaq OMX Stockholm. Before that he was Business Controller for various business areas within Pharmacia & Upjohn, such as Peptide Hormones, urology/gynaecology and metabolic diseases.

  • VP Business Development and Marketing
    Per Svedenhag
    VP Business Development and Marketing

    More than 20 years experience from product management, international marketing and business development primarily in the medical device industry. Previous companies include e.g.Gambro Engström, Racal-Redac, Siemens-Elema, XCounter and Innoventus. Per holds a degree of M.Sc. in Electrical Engineering from the Royal Institute of Technology, Stockholm.

  • Global Sales Director
    Tobias Bergenblad
    Global Sales Director

    Joined in 2015 after 12 years in international MedTech and LifeScience industry working with product launches and business development. He held several positions in sales and marketing with companies Hudson RCI, Maquet Critical Care and Aerocrine AB.
    Previous job was International Sales Director for Aerocrine AB where he successfully ran the ASIAPAC region.

  • Director Product Development
    David Melin
    Director Product Development

    Director Product Development since 2017. Joined SciBase in 2013 and has since worked with product development within hardware and system design. David holds a degree of M.Sc. in Mechanical Engineering focusing on Mechatronics from the Royal Institute of Technology, Stockholm and has previous experience of product development and test automation as a consultant.

  • Director Quality Assurance & Regulatory Affairs
    Niklas Jakobsson
    Director Quality Assurance & Regulatory Affairs

    Niklas brings a wealth of experience to SciBase with almost 20 years working in the MedTech industry. He has held positions within R&D, Production and Quality management for a number of different MedTech companies; many of which have been active on the US market. Niklas previously held the position of Quality manager at Ginolis AB in Uppsala where the electrode was manufactured before it was transferred to SciBase. This and his experience with the US market makes him a natural addition to the management team.

  • Supply Chain & Production Manager
    Anna Danström
    Supply Chain & Production Manager

    Anna has long experience within MedTech, working for a number of international companies such as St. Jude Medicals where she worked in a number of global technology transfer projects. Anna also has experience in working with FDA-related processes. She has previously been responsible for the development of electrodes at SciBase.

  • Managing Director (based in Munich, Germany)
    Dr. Emanuel von Kienlin
    Managing Director SciBase Germany

    Responsible for the German Market since 2015. Extensive experience in technical and medical products with track record to build highly motivated teams that achieve high success in complex national and international market environments. Broad industry experience in health care, automotive and aerospace. Emanuel has held senior positions within management, sales and marketing in companies as Danaher Corp., KaVo Dental and Lumenis. He earned his Ph.D. at University Kassel in cooperation with BMW Group.
    Current Assignments:
    Board Member and CEO at Cuban8 GmbH
    Holdings in SciBase:
    Holder of 3,000 shares.